Objective This multicentre randomised controlled trial aimed to compare the efficacy and safety of iguratimod (IGU) and hydroxychloroquine (HCQ) in patients with active primary Sjögren’s syndrome (pSS ...

Objective The primary objective was to assess sex differences in long-term functional deterioration and permanent work ...

Objective Recent advances in giant cell arteritis (GCA) management aim to reduce glucocorticoid (GC). We described changes in ...

Objective Idiopathic inflammatory myopathies (IIM) are a heterogenous group of conditions with substantial morbidity but ...

Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have key differences in clinical presentation, radiographic findings, comorbidities and pathogenesis to distinguish between these common forms ...

Background In SELECT-PsA 1, a randomised double-blind phase 3 study, upadacitinib 15 mg and 30 mg were superior to placebo and non-inferior to adalimumab in ≥20% improvement in American College of ...

Objective This international task force aimed to provide healthcare professionals and persons living with systemic lupus erythematosus (SLE) with consensus-based recommendations for physical activity ...

Background Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder lacking a gold-standard diagnostic ...

Objectives To develop evidence-based points to consider for cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory ...

Objectives The objectives are to evaluate variation in systemic disease activity (European Alliance of Associations For Rheumatology (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI)) over ...

Objective To evaluate the diagnostic pathway of patients affected by large vessel vasculitis (LVV) and to determine factors ...

Objectives To investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of nipocalimab in participants with moderate to severe active rheumatoid arthritis (RA) and inadequate response or ...